Docket No.: GNE.3230R1C69



INFORMATION DISCLOSURE STATEMENT

Goddard, et al.

App. No

10/063,596

Filed

May 3, 2002

For

SECRETED AND TRANSMEMBRANE

POLYPEPTIDES AND NUCLEIC ACIDS

ENCODING THE SAME

Examiner

Sandra L. Wegert

Art Unit

1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

October 18, 2006

(Date)

AnneMarie Kalser, Reg. No. 37,64

Mail Stop RCE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 14 references to be considered by the Examiner. Also enclosed are 14 non-patent literature references as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed with an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated.

Et. 18, 2006

Annel Marie Kaiser

Registration No. 37,649

Attorney of Record

Customer No. 30,313

(619) 235-8550

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application No.	10/063,596
Filing Date	May 3, 2002
First Named Inventor	Goddard, et al.
Art Unit	1647
Examiner	Sandra L. Wegert
Attorney Docket No.	GNE.3230R1C69

(Multiple sheets used when necessary)

SHEET 1 OF 2 Attorney Do

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevan Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
			·			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	BERNER, et al., "Clincopathological association of CD44 mRNA and protein expression expression in primary breast carcinomas" <i>Histopathology</i> (2003) 42:546-554.	
	2	BROOKS, et al., "cDNA array identification of genes regulated in rat renal medulla in response to vasoressin infusion" <i>Am J Physiol</i> (2003) 284:F218-F228.	
	3	CONRADS, et al., "A Combined Proteome and Microarray Investigation of Inorganic Phosphate-induced Pre-osteoblast Cells" <i>Mol. Cell Proteomics</i> , 4(9):1284-1296 (2005).	<u>-</u>
	4	CZUPALLA, et al., "Comparative study of proteinand mRNA expression during osteoclastogenesis" Proteomics 5:3868-3875 (2005).	
	5	GINESTIER, et al. 2002. "Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers" <i>Am. J. Pathol.</i> , 161:1223-1233.	
	1	KAWAMOTO et al., "Expression Profiles of Active Genes in Human and Mouse Livers," <i>Gene</i> , 1996 Sep 26;174(1):151-8.	
	7	KWONG, et al., "Synchronous global assessment of gene and protein expression in colorectal cancer progression" <i>Genomics</i> , 86:142-158 (2005).	
	8	LEDERMAN, et al. 1991. "A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4." <i>Molecular Immunology</i> , 28(11):1171-1181.	
	9	ODA, et al., "Expression of MDR1/p-glycoprotien and multidrug resistance-associated protein in childhood solid tumours" <i>Virchows Arch</i> (1997) 430:99-105	
	10	SAITO-HISAMINATO et al., Feb. 2002 (Genome-Wide Profiling of Gene Expression in 29 Normal Human Tissues with a cDNA Microarray. <i>DNA Research 9</i> , 35-45.	
	11	SUGG, et al., "Cytoplasmic staining of erbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia" Clinical Endocrinology (1998) 49:629-637.	

_	4		_
Fxai	miner	Signa	ature

Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

PTO/SB/08 Equivalent

	Application No.	10/063,596
INFORMATION DISCLOSURE	Filing Date	May 3, 2002
STATEMENT BY APPLICANT	First Named Inventor	Goddard, et al. OCT a
STATEMENT BY APPLICANT	Art Unit	1647
(Multiple sheets used when necessary)	Examiner	Sandra L. Weger
SHEET 2 OF 2	Attorney Docket No.	GNE.3230R1C69

<u> </u>	NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹	
	12	TOKUNAGA, et al. 2000. Application of quantitative RT-PCR using "TaqMan" technology to evaluate the expression of CK 18 mRNA in various cell lines. <i>J. Exp. Clin. Cancer Res.</i> , 19(3):375-381.		
	13	TOLER, et al., "Loss of communication in ovarian cancer" American Journal of Obstertrics and Gynecology, (2006)194:e27-e31.		
	14	WASHBURN, et al., "Protein pathway and complex clustering of correlated mRNA and protein expression analyses in Saccharomyces cerevisiae" Proc. Natl. Acad. Sci. 100(6): 3107-3112. (2003)		

3030521:101806/JJH

Examiner Signature Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.